Long-term maintenance deemed feasible in PV



Micrograph showing PV
Image courtesy of AFIP
Long-term maintenance with ropeginterferon alfa-2b is feasible, effective, and well-tolerated in patients with polycythemia vera (PV), according to researchers. In the ongoing phase 1/2 PEGINVERA study, patients have received ropeginterferon alfa-2b for a median of 4 years. After the first 2 years, patients switched from bi-weekly... [Read Article]

FDA clears use of reagents to detect hematopoietic neoplasia



Blood samples
Photo by Graham Colm
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails designed to aid the detection of hematopoietic neoplasia. This includes chronic and acute leukemias, non-Hodgkin lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. The ClearLLab reagents are... [Read Article]

Patients with thrombocytosis should be tested for cancers, team says



Platelets (blue) surrounded
by red blood cells
Image by Graham Beards
Researchers have found evidence to suggest that thrombocytosis is a strong predictor of cancer, particularly lung and colorectal cancer. The team therefore believes patients with thrombocytosis should be evaluated for an underlying malignancy, as such investigation could speed up cancer diagnosis and... [Read Article]

Company again withdraws application for pacritinib



Primary myelofibrosis
CTI BioPharma has withdrawn its application for marketing authorization of pacritinib (Enpaxiq) in the European Union, according to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The company was seeking approval for pacritinib, a JAK2/FLT3 inhibitor, to treat splenomegaly or symptoms of myelofibrosis (MF) in adults... [Read Article]

Trial supports early treatment of lower-risk ET



prescriptions_Credit_CDC_230.jpg
Prescription medications
Photo courtesy of CDC

Results from the ARETA trial suggest patients with essential thrombocythemia (ET) can benefit from early treatment even if they are not considered high-risk. In this phase 3 trial, non-high-risk patients were less likely to experience ET-related cardiovascular events or disease progression if they received extended-release anagrelide rather than... [Read Article]

Novel interferon appears safer than HU in PV



ash2016-escalators-JS-230-v2.jpg
Attendees at the 2016 ASH Annual Meeting
SAN DIEGO—Results of the PROUD-PV trial suggest ropeginterferon alfa-2b is safer than hydroxyurea (HU) for patients with polycythemia vera (PV).In this phase 3 trial, ropeginterferon alfa-2b demonstrated non-inferiority to HU with regard to complete hematologic response (CHR).Ropeginterferon alfa-2b also had a significantly better overall safety profile.Unlike the patients... [Read Article]

Pacritinib bests BAT despite study truncation



Mascarenhas_John_ASH2016-240.jpg
John Mascarenhas, MD

The JAK2/FLT3 inhibitor pacritinib significantly reduces spleen volume and symptoms in patients with myelofibrosis and low platelet counts, compared to best available therapy (BAT), according to results of the PERSIST-2 trial. In this phase 3 trial, BAT included the JAK1/2 inhibitor ruxolitinib. And pacritinib demonstrated benefits over BAT despite a truncated trial.... [Read Article]